Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| ContraFect Corporation | CFRX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.2318 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.2318 | 0.2318 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.20 - 2.94 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.2318 | USD |
ContraFect Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 2.48M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ContraFect News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CFRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.3242 | 0.326 | 0.20 | 0.2596457 | 129,534 | -0.0924 | -28.50% |
| 1 Year | 1.57 | 2.94 | 0.20 | 1.74 | 890,667 | -1.34 | -85.24% |
| 3 Years | 332.80 | 380.40 | 0.20 | 23.45 | 1,873,283 | -332.57 | -99.93% |
| 5 Years | 38.992 | 1,060.00 | 0.20 | 69.64 | 1,315,165 | -38.76 | -99.41% |
ContraFect Description
| ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lysin exebacase has a targeted spectrum of activity, meaning that it kills specific species of Staphylococci or closely related bacteria. Its IND candidate, CF-370, targets resistant gram-negative bacteria including Pseudomonas aeruginosa (P. aeruginosa). Its advanced clinical candidate, exebacase, is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis. |
